This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. A. GOLD, M.D.

AMA Arch Intern Med. 1957;100(2):209-213.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since the introduction of digitalis into the practice of medicine by William Withering, in 1785, as a diuretic,¹ numerous preparations have been tried in the search for an ideal drug for cardiac disease, one that is not only effective but also less toxic. Goodman and Gilman² stated that a "nontoxic digitalis does not exist. A digitalis preparation which will not cause poisoning when given in excess is also one which will not exert any therapeutic effect."

Reports of the use of acetyldigitoxin have appeared in the European literature,^3-6 and they have stated that it is an effective, rapidacting, well-absorbed, fairly rapidly excreted, well-tolerated digitalis preparation, but there have been relatively few American clinical trials.^{7 -16}

Acetyldigitoxin (Acylanid) is a purified glycoside prepared first by Stoll and Kreis ¹⁷ by the enzymatic cleavage of a glucose molecule from lanatoside A, the glycoside

derived from Digitalis lanata. . . . [Full Text PDF of this Article]

Author Affiliations
Butte, Mont.

Footnotes
Submitted for publication Dec. 22, 1956.

Presented during the Montana-Wyoming Regional Meeting of the American College of Physicians, Great Falls, Mont., Nov. 16-17, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?